Zoledronate dose comparison study for patients with a proximal femur fracture

Comparative study of Zoledronate 5 mg and 2.5 mg in patients with a proximal femur fracture

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071240037

Enrollment

Registered

2024-07-22

Start date

2024-11-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proximal femur fracture osteoporosis

Interventions

Patients with a proximal femur fracture are randomly assigned to be treated with 5 mg or 2.5 mg of zoledronate.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients receiving osteoporosis treatment after surgical treatment for a proximal femur fracture (fragility fracture)

Exclusion criteria

Exclusion criteria: Patients with severe renal dysfunction (eGFR<35 mL/min/1.73 m2)

Design outcomes

Primary

Measure	Time frame
Rate of change in bone mineral density after 24 months of administration and group difference in rate of change.	—

Secondary

Measure	Time frame
At 12 and 24 months after administration, rate of change in bone mineral density and bone-related markers, and group differences in rate of change. Amount of change in body temperature and pain up to 7 days after administration. At 7 days after administration, amount of change in serum Cre and Ca, and group differences in amount of change.	—

Contacts

Public ContactKo Chiba

Nagasaki University Graduate School of Biomedical Sciences

kohchiba@estate.ocn.ne.jp+81-95-819-7530

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026